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Abstract
Background: Radiotherapy for head and neck cancer results in severe and chronic salivary gland dysfunction in
most individuals. This results in significant side effects including xerostomia, dysphagia, and malnutrition which are
linked to significant reductions in patients’ quality of life. Currently there are few xerostomia treatment approaches
that provide long-term results without significant side effects. To address this problem we investigated the
potential for post-therapeutic IGF-1 to reverse radiation-induced salivary gland dysfunction.
Methods: FVB mice were treated with targeted head and neck radiation and significant reductions in salivary
function were confirmed 3 days after treatment. On days 4-8 after radiation, one group of mice was injected
intravenously with IGF-1 while a second group served as a vehicle control. Stimulated salivary flow rates were
evaluated on days 30, 60, and 90 and histological analysis was performed on days 9, 30, 60, and 90.
Results: Irradiated animals receiving vehicle injections have 40-50% reductions in stimulated salivary flow rates
throughout the entire time course. Mice receiving injections of IGF-1 have improved stimulated salivary flow rates
30 days after treatment. By days 60-90, IGF-1 injected mice have restored salivary flow rates to unirradiated control
mice levels. Parotid tissue sections were stained for amylase as an indicator of functioning acinar cells and
significant reductions in total amylase area are detected in irradiated animals compared to unirradiated groups on
all days. Post-therapeutic injections of IGF-1 results in increased amylase-positive acinar cell area and improved
amylase secretion. Irradiated mice receiving IGF-1 show similar proliferation indices as untreated mice suggesting a
return to tissue homeostasis.
Conclusions: Post-therapeutic IGF-1 treatment restores salivary gland function potentially through normalization of
cell proliferation and improved expression of amylase. These findings could aid in the rational design of therapy
protocols or drugs for the treatment of radiation-induced salivary gland dysfunction in patients who have
completed their anti-cancer therapies.
Background
The treatment of head and neck cancer commonly
involves fractionated radiation therapy which results in
significant side effects including xerostomia, dysphagia,
and increased infection rates in most patients [1-3].
Although attempts are made to limit radiation exposure
to spare normal tissues, the close proximity of the sali-
vary glands to the treatment field leads to impairment
of physiological function and secondary side effects that
impact quality of life for patients [4]. A reduction of
saliva flow rates by 50-60% with accompanying changes
in saliva composition ensues during the first week of
continued radiation therapy which has been associated
with a loss of acinar cells and glandular shrinkage [5,6].
Serous acinar cells of the parotid gland are the main
contributor of protein and water to the composition of
saliva [7,8]. It has been shown in humans that radiation-
induced defects in amylase production by the parotid
acinar cells lead to significant decreases in amylase con-
centration in stimulated saliva [9]. These immediate
pathophysiological and structural changes may contri-
bute to the development of chronic symptoms such as
malnutrition, mucositis, and permanent reduction in
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cement with fibrotic tissue [10-12].
Current treatment approaches focus mainly on pre-
venting radiation-induced xerostomia. The only preven-
tative therapy currently available is amifostine which is
linked to unfavorable side effects such as hypotension,
vomiting, and allergic reaction with a high discontinua-
tion rate [13]. A promising drug for xerostomia preven-
tion is tempol, which is currently being evaluated in
clinical trials [14]. Since reductions in salivary flow rates
are believed to be the cause for many of the secondary
complications, palliative therapy with cholinergic ago-
nists such as pilocarpine and cevimeline have been pro-
posed to stimulate salivary flow [15,16]. However, these
treatments have transient efficacy and limited success
due to side effects. Promising research has been con-
ducted in recent years that have the potential to affect
the development of new treatment approaches for sali-
vary gland dysfunction including growth factors, gene
transfer, artificial salivary glands, and stem cell trans-
plantation (reviewed in [17]).
A number of animal models have been utilized in
order to understand the sensitivity of the salivary glands
to therapeutic radiation (reviewed in [17]). Consistent
with the human studies, all of these models demonstrate
the acute and chronic loss of function; however the
mechanisms responsible for the alterations in glandular
physiology are debated. The mechanism of loss of acinar
cell area seems to involve an apoptotic process which
appears to be mediated through a p53-dependent path-
way [18,19]. Transgenic mice expressing a constitutively
activated mutant of Akt1 (myr-Akt1) suppressed radia-
tion-induced apoptosis in vitro and in vivo by regulating
the activation of p53 [18]. The use of intravenous injec-
tion of recombinant IGF-1 before radiation exposure
has been shown to activate endogenous Akt in the sali-
vary glands and suppress radiation-induced apoptosis
[16]. Importantly, the suppression of apoptosis corre-
lated with improved salivary function following radiation
treatment.
Levels of radiation-induced apoptosis in mouse models
appear to be dose dependent; however, the reductions in
salivary flow rate are similar regardless of radiation dose
[16,18-20]. Salivary glands present with significantly ele-
vated levels of apoptotic cells within the first 24 hours
after exposure to a single dose of ionizing radiation of
which the majority are acinar cells [16,18-20]. In animal
models of radiation-induced damage, reductions in sali-
vary flow rates have been reported within 3 days post-
treatment and persist out to one year (reviewed in [17]).
In contrast to clinical studies, little data is available
regarding the recovery from radiation-induced salivary
gland dysfunction in animal models. Because apoptosis
has been reported to occur initially following radiation
in parotid salivary glands, the rate of acinar cell prolif-
eration may provide further insight into restoration of
radiation-induced tissue damage that leads to normal
salivary flow rates in mice treated with post therapy
I G F - 1 .T h ec u r r e n ts t u d yi n v estigates the relationship
between a single dose radiation exposure (5 Gy) and the
ability of post radiation therapy administration of
recombinant IGF-1 to restore salivary gland function.
Methods
Mice
Female FVB mice between 4-5 weeks old, obtained from
Taconic (Taconic, Hudson, NY) were used for all
experiments. Animals were maintained on a 12 h light/
dark cycle in accordance with the protocols approved by
the University of Arizona Institutional Animal Care and
Use Committee (IACUC).
Radiation Treatment
Mice were anesthetized intraperitoneally with avertin
(tribromoethanol) in a dose of 0.4 to 0.6 mg/kg prior to
radiation treatment. Mice were then irradiated with a
single fraction of radiation (5 Gy) to the head and neck
region (Cobalt-60 Teletherapy unit from Atomic Energy
of Canada Ltd Theratron-80) as previously described
(day 0; figure 1A) [19]. This results in irradiation of the
submandibular, sublingual, parotid, and minor salivary
glands. The 5 Gy radiation dose was chosen based on
our previous work demonstrating the dose caused ele-
vated levels of p53 protein, activation of apoptosis,
absence of cell cycle arrest, and loss of salivary function
[18,19,21,22]. The rest of the body (below clavicle) was
shielded with >6 mm thick lead which blocked ~75% of
the radiation to avoid systemic effects of radiation.
Radiation dosimetry calculations and maintenance of the
cobalt source are conducted by the Experimental Radia-
tion Shared Service of the Arizona Cancer Center.
Day 3 stimulated salivary flow rates were used to con-
firm significant reductions due to radiation exposure
(figure 1B) and then all animals were randomized into
final treatment groups. A sub-group of animals were
then injected with 5 μg recombinant IGF-1 (GroPrep,
Adelaide, Australia) for five consecutive days (day 4-8;
figure 1A) or injected with vehicle (PBS+BSA). FVB
mice were injected intravenously through the tail vein
with 5 μg recombinant IGF-1 (total volume of 100 μl)
on days 4 through 8 (~24 hours apart) after radiation
treatment as previously described [16]. This dose of
IGF-1 was chosen because it induces maximal activation
of signal transduction pathways in the salivary gland
and suppresses radiation-induced loss of salivary gland
function [16]. Animals were maintained and treated in
accordance with protocols approved by the University of
Arizona IACUC.
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FVB mice were injected i.p. with carbachol (0.25 mg/kg
body weight) as previously described [18] and saliva was
collected for 5 min. on days 3, 9, 30, 60, and 90 after
radiation treatments. Total saliva was collected by
vacuum aspiration from 10-23 mice per treatment
group as previously described [23] on ice immediately
following carbachol injection into pre-weighed tubes
and stored at -80°C. Total proteins present in the col-
lected saliva from 7-8 mice were analyzed by resolving
25 μg total protein on a 10% SDS-PAGE gel, transferred
to Immunobilon membrane (Millipore Corporation,
Bedford, MA), and immunoblotted with anti-amylase
(Sigma-Aldrich, St. Louis, MO). Secondary antibody was
conjugated with horseradish peroxidase (anti-HRP con-
j u g a t e dr a b b i ta n t i b o d y ;B i o-Rad, Hercules, CA) and
enhanced chemiluminescence lighting (Pierce Chemical
Company, Rockford, IL) was used according to the man-
ufacturer’s instructions to detect salivary amylase.
Histology
Following excision, tissues were immediately fixed in
10% neutral buffered formalin for 24 hours, transferred
to 70% ethanol, and embedded in paraffin. Sections of
Figure 1 Experimental setting (A) and reduction in salivary flow rates on day 3 following radiation (B). The head and neck region of FVB
mice was exposed to a single dose of 5 Gy radiation. Stimulated salivary flow rates were determined as described in the materials and methods
section on day 3 with 81 animals in the untreated (UT) and 72 animals in the treated group. Significant differences (p < 0.05) were determined
using an ANOVA followed by a Bonferroni test. (*) in figure 1B over 5Gy treatment group indicates significant differences between groups.
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processed for standard staining with hematoxylin and
eosin by the Histology Service Laboratory in the Depart-
ment of Cell Biology and Anatomy at the University of
Arizona.
Quantification of acinar cell area
Tissue sections from mice (3-8 mice per group) treated
with targeted head and neck radiation were stained for
amylase (Sigma-Aldrich, St. Louis, MO) as previously
described [24]. Briefly, slides were rehydrated and antigen
retrieval performed as described for PCNA. Slides were
blocked with 0.5% NEN at room temperature for 1 hour
then incubated in anti-amylase primary antibody (1:500)
overnight at 4°C. On day 2, slides were washed and incu-
bated in anti-rabbit Cy2-conjugated secondary antibody
(1:500) at room temperature for 1 hour, counterstained
with DAPI, then mounted with 50% glycerol in 10 mM
Tris-HCl. Fluorescent images were visualized on a Leica
DM5500 Microscope System and digitally captured with
a Spot Pursuit 4 Megapixel CCD camera (Diagnostic
Instruments, Inc., Sterling Heights, MI). A figure insert
shows a representative image demonstrating the selective
staining for acinar cell area. Morphometric analysis was
performed with ImagePro 7.0 software (Media Cyber-
netics, Silver Spring, MD). Positive areas were deter-
mined for 25 fields of view (FOV = 0.39 mm
2)a n dw e
were able to obtain a coefficient of variation of <7%,
which did not improve with greater numbers of observa-
tions per section. Amylase-positive cell area was collected
throughout both parotid glands of each mouse on days
30, 60, and 90 following radiation. Data are expressed as
the percentage of amylase positive area to the total area
of the gland and the threshold fluorescence range was
equivalent for all slides imaged.
Quantification of amylase protein
The collected saliva samples from day 30 were evaluated
for total amylase protein using the Bio-Rad Experion
System (3-8 mice per group). Samples were loaded into
ap r i m e dE x p e r i o nC h i pa n dr u nu s i n gt h eE x p e r i o n
Software Protein260 Assay. Proteins of different molecu-
lar weights were visualized as bands in each sample.
Analysis was done from bands located at or around the
molecular weight of amylase (54 kDa). Percent total
amylase was calculated using the Experion software and
graphed for each treatment group.
Quantification of proliferation
For evaluation of acinar and ductal cell proliferation,
unstained tissue sections were processed for anti-PCNA
(proliferating cell nuclear antigen, Santa Cruz Biotech-
nology Inc., Santa Cruz, CA) immunohistochemistry 9,
30, 60, and 90 days after treatment as previously
described [18]. Briefly, slides were heated to 37°C for 30
min. and rehydrated in histoclear, graded alcohols, and
distilled water washes. Nonspecific peroxidase activity
was quenched with 0.3% H2O2. For antigen retrieval,
slides were placed in citrate buffer (pH 6.0) and heated
in a microwave oven twice for 5 min, and allowed to
cool for 20 min. After washes, the slides were treated
according to manufacturer’s instructions (Vectastain
Elite ABC kit, PK-6101, Vector Laboratories Inc.,
Burlingame, CA). Color development was achieved with
Biogenex DAB incubation for 6 to 8 minutes. Slides
were lightly counterstained with Gill’s hematoxylin,
dehydrated, and mounted in Permount. Tissue sections
were observed by standard light microscopy and photo-
micrographs were taken with a Leica DM5500 with a
4 megapixel Pursuit camera. Positive acinar cells were
counted separately from positive ductal cells due to
proposed progenitor cells present within the ductal cell
network [25]. Individual means for quantification of
PCNA positive acinar and ductal cells were determined
by averaging the number of positive cells/total number
of cells from a minimum of three fields of view/animal
(3-5 mice per group; total cells counted ranged from
3,000 to 6,000 per mouse).
Statistics
Comparison of PCNA and acinar area data, amylase pro-
tein content on day 30, as well as normalized saliva flow
rates was accomplished by a one-way ANOVA followed
by a post-hoc Bonferroni multiple-comparison test. Saliva
flow rates were normalized to the respective untreated
FVB group for days 3, 30, 60, and 90. Statistical analysis
and graphical generation of data were done using Graph-
Pad Prism software (version 5.0, San Diego, CA).
Results
Stimulated salivary flow rates are restored in mice
receiving post therapy IGF-1
FVB mice exposed to a single radiation dose exhibit sig-
nificant (P< 0.05, one-way ANOVA) reductions in sali-
vary function (decreased 43-50%) throughout the time
course (figure 2A, B, and 2C) consistent with previously
published studies in other animal models [12,26,27]. In
contrast, injection with IGF-1 on days 4-8 following
radiation increased salivary flow rates to 72% of the
untreated control on day 30 compared to irradiated FVB
mice (figure 2A). Further increases in salivary flow rates
on days 60 and 90 in irradiated mice injected with
IGF-1 result in return to untreated flow rates (93 and
81% of untreated controls, figure 2B and 2C). Adminis-
tration of recombinant IGF-1 to unirradiated FVB mice
on days 4-8 did not show significant changes in salivary
flow rates at any of the time points evaluated (85-100%
of untreated controls) indicating that IGF-1 does not
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These functional data suggest that post therapy IGF-1
can alter the response of salivary glands to radiation
damage leading to restoration of function.
Post therapy IGF-1 restores functional acinar cell area and
amylase secretion in irradiated mice
On all days, a consistent 14-24% reduction in amylase-
positive cell area is measured for FVB mice irradiated
with a single 5 Gy dose that received vehicle injections.
This reduction was significantly different from untreated
FVB, IGF-1 injected, and irradiated mice receiving post
therapy IGF-1 (P< 0.05, one-way ANOVA). The acinar
cell areas for untreated FVB and IGF-1 injected mice
are not significantly different at any time point. Post
therapy injections of IGF-1 on days 4-8 after irradiation
lead to a significant increase in amylase-positive acinar
cell area which is not significantly different from both
unirradiated groups (93-98% of untreated controls,
figure 3). In addition, evaluation of the total amylase
protein content in stimulated saliva on day 30 shows
that restoration of acinar cell areas in IGF-1 injected
mice indeed increase amylase content in stimulated sal-
iva (90% of untreated controls, figure 4). In contrast,
irradiated mice secrete less amylase (decreased 29%)
compared to unirradiated control saliva samples. The
increase in amylase-positive cell area and amount of
amylase protein in stimulated saliva on day 30 (figure 4)
in irradiated mice receiving IGF-1 correlates with
increases in stimulated salivary flow rates on the corre-
sponding time points (figure 2A, B, and 2C).
Proliferation indices return to untreated levels in
irradiated mice receiving post-therapy IGF-1
F V Bm i c ee x p o s e dt o5G yh a v ea4 - f o l di n c r e a s ei n
PCNA positive salivary acinar cells at days 9 and 30
when compared to untreated controls (P< 0.05, one-way
ANOVA, figure 5A). At days 60 and 90, irradiated FVB
mice continue to show elevated PCNA-positive acinar
cell levels that is statistically higher than untreated con-
trols (P< 0.05, one-way ANOVA). In contrast, the num-
ber of PCNA positive acinar cells in irradiated mice
injected with IGF-1 gradually decreases from elevated
levels (2-3 fold) on days 9 and 30 to levels similar to
untreated mice on days 60 and 90 (figure 5A). At later
time points (days 60-90), the percentage of PCNA posi-
tive acinar cells in mice receiving post-therapy IGF-1
are not statistically different from untreated controls
(P< 0 . 0 5 ,o n e - w a yA N O V A ) .I ni r r a d i a t e dm i c e ,t h e
level of PCNA positive ductal cells remains significantly
elevated throughout the observation period similar to
the profile detected in acinar cells (P< 0.05, one-way
ANOVA), figure 5B). Interestingly, the level of PCNA
positive ductal cells in irradiated mice receiving IGF-1
only differs from untreated control mice on day 30. This
profile within the ductal cells of irradiated IGF-1
injected mice is strikingly different from the profile of
the acinar cells which demonstrate a gradual decrease in
PCNA (compare 5A and B).
Discussion
Radiation treatment of head and neck cancer patients
causes significant chronic damage to the salivary glands
Figure 2 Salivary gland dysfunction is reversed in mice
receiving post therapy IGF-1. The head and neck region of FVB
mice was exposed to a single 5 Gy radiation dose and mice
received injections of IGF-1 or vehicle on days 4-8 as depicted in
figure 1A. Stimulated salivary flow rates were determined as
described in the materials and methods section on days 30 (A), 60
(B), and 90 (C). Irradiated flow rates were normalized to
corresponding unirradiated controls after the radiation treatment.
The graph represents the mean and standard error of the mean of
all data from 10-23 mice per treatment group. Significant
differences (p < 0.05) were determined using an ANOVA followed
by a post-hoc Bonferroni multiple-comparison test. Treatment
groups with the same letters are not significantly different from
each other within the same day.
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a single 5 Gy radiation dose and mice received injections of IGF-1 or vehicle on days 4-8 as depicted in figure 1A. Parotid glands were removed
on days 30 (A), 60 (B), and 90 (C) after the radiation treatment. Tissues were embedded into paraffin and immunohistochemistry was performed
according to the materials and methods section. The insert is a representative image with amylase-positive acinar cells (green), cytokeratin-
positive ductal cells (red), and cell nuclei (blue). The graph represents the percentage area of amylase-positive cells in the field of view. All data
are composed of the mean and standard error of the mean from 3-8 mice per group. Significant differences (p < 0.05) were determined using
an ANOVA followed by a post-hoc Bonferroni multiple comparison test. Treatment groups with the same letters are not significantly different
from each other within the same day.
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improve the patients’ quality of life. The current findings
indicate that post therapy injections of IGF-1 following
radiation restore salivary gland function (figure 2),
which poses several clinical advantages. Implications
include the possibility of restoring salivary gland func-
tion in specific patients by delivering an IGF1-type com-
pound to restore deficient salivary gland function, even
after radiation therapy.
The reduction in stimulated salivary flow rates for ani-
mals receiving a single radiation dose of 5 Gy is signifi-
cant throughout the 90 day observation period (figure 2).
These findings are in agreement with previous studies
using single doses of radiation (1-5Gy) [16,19]. Post ther-
apy administration of IGF-1 on days 4-8 after radiation
exposure significantly increases salivary flow rates at all
time points. On days 60 and 90 flow rates have been
restored to untreated levels (figure 2). This further estab-
lishes a critical role for IGF-1 in the signaling pathways
that manage the cellular response to radiation in the sali-
vary glands. It also suggests that post therapy activation
of specific downstream molecules may be an effective tar-
geted therapy for the restoration of salivary gland
function.
Loss of acinar cells in response to radiation has been
widely discussed. While significant levels of apoptosis
immediately following radiation have been observed in
mice [16,18-20], the presence of apoptosis in irradiated
rats has been more variable [28-30]. Because acinar cells
c o n t r i b u t eam a j o r i t yo fs a l i v ac o n s t i t u e n t si n c l u d i n g
amylase and water, loss of these cells would impair nor-
mal saliva composition and lead to reduction in saliva
flow. Our results indicate that reduction of stimulated
salivary flow rates as a physiological parameter is closely
Figure 4 Post therapy IGF-1 restores amylase content in
stimulated saliva 30 days following radiation. The head and
neck region of FVB mice was exposed to a single 5 Gy radiation
dose and mice received injections of IGF-1 or vehicle on days 4-8 as
depicted in figure 1A. In (A), stimulated saliva samples from figure
2A were collected and analyzed for total protein content as
described in the materials and methods section. The graph
represents the percentage of amylase protein (ranging from 50-57
kD). All data are composed of the mean and standard error of the
mean from 7-8 mice per group. Significant differences (p < 0.05)
were determined using an ANOVA followed by a Bonferroni test. (*)
in figure 4A indicates significant differences between irradiated mice
receiving post-therapy IGF-1 or vehicle. A representative Western
blot as described in the materials and methods section of day 30
saliva samples is shown in (B).
Figure 5 Proliferation of parotid acinar and ductal cells
following radiation (single 5 Gy dose) in FVB or IGF-1 injected
mice. The head and neck region of FVB mice was exposed to a
single 5 Gy radiation dose and mice received injections of IGF-1 or
vehicle on days 4-8 as depicted in figure 1A. Parotid glands were
removed 9, 30, 60, and 90 days after the radiation treatment. Tissues
were embedded into paraffin and immunohistochemistry was
performed using an antibody against PCNA. The graph represents
the number of acinar cells with positive PCNA staining as a
percentage of the total number of acinar (A) or ductal (B) cells in
the field of view. The data is displayed as the mean and the
standard error of the mean of all data from 3-8 mice per group.
Significant differences (p < 0.05) were determined using an ANOVA
followed by a post-hoc Bonferroni multiple-comparison test.
Treatment groups with the same letters are not significantly
different from each other within the same time point.
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in parotid glands (figure 3). The percentage of amylase
positive cells is a useful indicator for the evaluation of
actively secreting parotid acinar cells [9]. Our findings
further indicate that the loss of amylase positive cells is
correlated with a decrease in amylase protein secretion
(figure 4). Post therapy administration of IGF-1 to irra-
diated mice results in significant increases of amylase-
positive cells over the course of the observation period
compared to irradiated animals that received vehicle
alone (figure 3). While irradiated animals have consis-
tently reduced areas of amylase-positive cells on days
30, 60, and 90, administration of IGF-1 after radiation
results in increased amylase-positive cells and improved
amylase secretion indicative of a restoration of function-
ing acinar cells (figures 3 and 4). A common observation
in salivary glands exposed to radiation is atrophy and
loss of glandular weight indicative of cell loss (reviewed
in [17]), and our results implicate that functional acinar
cell area is restored in animals receiving post therapy
IGF-1 injections.
An interesting finding of our study is the influence of
post therapy IGF-1 administration on PCNA, a marker
of cell proliferation. Tissue homeostasis is maintained
by keeping a balance between cell growth and cell
death. Salivary glands, unlike other radiosensitive tissues,
consist of highly differentiated cells that proliferate
slowly (reviewed in (24)). In our study, we observe
increased levels of PCNA positive acinar cells in animals
receiving a single dose of 5 Gy (figure 5) which could be
indicative of compensatory proliferation [31]. In rapidly
cycling tissues, compensatory proliferation is a mechan-
ism to replace lost cells; however in slowly cycling tis-
sues, compensatory proliferation correlates with loss of
function [31-33]. Our study concurs with these studies
in that radiation-induced compensatory proliferation in
the salivary gland correlates with reduced physiologic
function. It is feasible that the cells actively cycling in
the salivary gland have an undifferentiated phenotype
that does not produce an appreciable amount of saliva.
While the level of PCNA positive acinar cells remains
significantly elevated in irradiated animals, mice receiv-
ing post therapy IGF-1 decreased the levels of PCNA
positive acinar cells to back to control levels on days 60
and 90 (figure 5A). Our study corroborates radiation-
induced compensatory proliferation that has been
reported in the submandibular salivary glands of mice
[34,35] and the parotid salivary glands of rats [36]. Inter-
estingly, administration of pilocarpine prior to radiation
treatment of rats resulted in increased compensatory
proliferation and preservation of salivary function
[36,37]. One explanation for the difference between our
study and the pilocarpine study is the timing of admin-
istration. Our study evaluated alterations in proliferation
indices using a post-therapy model (figure 1A) whereas
pilocarpine was administered prior to radiation treat-
ment [36].
Currently the salivary gland stem cell is unknown;
however, there is growing evidence that progenitor cells
are present within the ductal cell network. Immunohis-
tochemical staining of submandibular salivary glands for
the stem cell marker c-kit revealed its localization to the
excretory duct [25]. In addition, transplantation of sali-
vary cells enriched for c-kit into irradiated mouse sali-
vary glands restores salivary gland function [25]. Our
results in irradiated mice demonstrate an increase in
PCNA positive ductal cells across the entire time course
similar to the acinar cells (figure 5). In contrast, mice
receiving post therapy IGF-1 have an increase in PCNA
positive ductal cells only at the day 30 time point after
radiation treatment. It is possible that IGF-1 may transi-
ently influence the stem/progenitor population within
the ductal network in order to restore salivary gland
function; however more studies are required to test this
hypothesis.
One potential concern for the use of growth factors
such as IGF-1 for clinical applications is the effect as a
tumor promoter. However, salivary gland tumors were
not detected in any of the animals that received five
consecutive injections of IGF-1 in our studies. Further-
more, it is more likely that drugable analogs of IGF-1
specific to the tissue or pathways involved would be
developed and administered clinically. In addition, the
salivary glands could be specifically treated through can-
nulation of the salivary duct. The long-term translation
of this study involves the identification of these pathway
specific molecules that could be utilized to specifically
target and restore salivary gland function following clini-
cal radiation therapy.
Conclusions
The results of our study provide further support for the
involvement of IGF-1 or analogous compounds in the
preservation and restoration of salivary glands following
radiation which can lead to diminished side effects and
provide head and neck cancer patients with the possibi-
lity for improved quality of life.
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